Antagonists of IL-6 to raise albumin and/or lower CRP
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
1. A method of reducing serum C-reactive protein (“CRP”) level in a patient with an allergic condition wherein interleukin-6 (“IL-6”) is elevated by administering an effective amount of an anti-IL-6 antibody comprising the variable heavy and light chain polypeptides of SEQ ID NO:657 and SEQ ID NO:709 respectively and the constant regions of SEQ ID NO:588 and 586 and monitoring the patient to assess the reduction in the patient's serum CRP level.
2. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment is aglycosylated.
3. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency at most once per period of approximately four weeks.
4. The method of claim 3 , wherein the patient's serum CRP level remains decreased and/or serum albumin level remains raised for an entire period intervening two consecutive anti-IL-6 antibody administrations.
5. The method of claim 1 , further comprising: measuring the patient's serum CRP level prior to administration of the IL-6 antibody, and administering the IL-6 antagonist if the patient's serum CRP level is at least approximately 5 mg/L.
6. A method of increasing serum albumin level in a patient with an allergic condition where interleukin-6 (“IL-6”) is elevated by administering an effective amount of an anti-IL-6 antibody comprising the variable heavy and light chain polypeptides of SEQ ID NO:657 and SEQ ID NO:709 respectively and the constant regions of SEQ ID NO:588 and 586, and monitoring the patient to assess the increase in the patient's serum albumin level.
7. The method of claim 6 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency at most once per period of approximately four weeks.
8. The method of claim 6 , further comprising: measuring the patient's serum albumin level prior to administration of the IL-6 antibody, and administering the IL-6 antagonist if the patient's serum albumin level is less than approximately 35 g/L.
9. A method of reducing a patient's serum CRP level and increasing the patient's serum albumin level in a patient with an allergic condition wherein interleukin-6 (“IL-6”) is elevated by administering an effective amount of an anti-IL-6 antibody comprising the variable heavy and light chain polypeptides of SEQ ID NO:657 and SEQ ID NO:709 respectively and the constant regions of SEQ ID NO:588 and 586, and monitoring the patient to assess the reduction in the patient's serum CRP level and the increase in the patient's serum albumin level.
10. The method of claim 9 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency at most once per period of approximately four weeks.